Navigation Links
Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification
Date:1/31/2011

CHADDS FORD, Pa., Jan. 31, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today that its partners, Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc.,  have received a Paragraph IV Certification Notice from Mylan Technologies Inc. advising of the filing of an Abbreviated New Drug Application (ANDA) for a generic version of LIDODERM® (lidocaine topical patch 5%).

The company is currently reviewing the details of this notice from Mylan. Endo intends to vigorously defend LIDODERM's intellectual property rights and will pursue all available legal and regulatory pathways in defense of LIDODERM.

The Paragraph IV certification notice refers to U.S. Patent Nos. 5,741,510 and 5,827,529, which cover the formulation of LIDODERM, a topical patch to relieve the pain of postherpetic neuralgia launched in 1999. These patents are listed in the U.S. Food and Drug Administration's (FDA) Orange Book and expire in March 2014 and October 2015, respectively.

Citizen Petition

With respect to Endo's regulatory approach, the company submitted a Citizen Petition in 2006 in reaction to a proposal by FDA's Office of Generic Drugs that would diverge from applicable regulations and standards of practice regarding bioequivalence. The company is requesting that the agency reconsider its departure from its longstanding general rule of requiring clinical endpoint bioequivalence studies for locally acting topical generic drug products, including those that reference LIDODERM. To ensure the safe and effective equivalence of any generic version to LIDODERM, which acts locally in the skin, Endo believes that FDA must return to its established standard of clinical endpoint bioequivalence studies.

About Endo

Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company, focused on high-value branded products and sp
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013  Specialty Coating Systems is ... Parylene coating technologies: SCS microRESIST™ Antimicrobial Parylene ... Parylene with antimicrobial properties to effectively eliminate ... (Logo: http://photos.prnewswire.com/prnh/20130618/DE33772LOGO ) ... and continue to pose a challenge to ...
(Date:6/18/2013)... 18, 2013 MPR is excited to unveil ... edition. It,s all part of an ongoing effort to freshen ... practitioners for over 28 years. (Photo: ... evolution MPR has expanded upon its foundation as ... to include an increasing array of clinical and practice management ...
(Date:6/18/2013)... INDIANAPOLIS , June 18, 2013 The ... LLY ) has declared a dividend for ... on outstanding common stock. The dividend ... at the close of business on August 15, 2013. ... a growing portfolio of pharmaceutical products by applying the ...
Breaking Medicine Technology:Specialty Coating Systems Announces New Antimicrobial Parylene Technology 2MPR Sports a Bold New Look 2
... ® Products is pleased to announce ... was developed to support the recent introduction of LimbO Waterproof Protectors ... Products in the United Kingdom, LimbO Waterproof Protectors enable children and ... cast or a bandage. The waterproof cover is simply slipped on ...
... CITY, Feb. 21, 2012 Genomma Lab Internacional, S.A.B. de ... a non-binding proposal to acquire all of the outstanding shares ... ) common stock for $16.60 dollars per share in cash. ... including Prestige,s net debt. Genomma,s all-cash proposal ...
Cached Medicine Technology:LimbO® Products Launches New U.S. Website 2Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 2Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 3Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 4Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 5
(Date:6/18/2013)... 2013 Senior drug regulatory officials from mainland ... to discuss—for the first time in the U.S.—the need for ... the regulatory process in a timely manner. Representatives from the ... respective best practices and processes in drug review during the ... at the DIA 2013 49th Annual Meeting . ...
(Date:6/18/2013)... Seven-year-old Riley Salz of Encino, California, is ... 40 hours a week of applied behavior analysis (ABA) ... for Autism and Related Disorders (CARD). Riley has been ... experienced remarkable progress, including learning to speak, starting conversations, ... journey through autism is now featured in CARD’s “Mission ...
(Date:6/18/2013)... have discovered and mapped the signaling network between two ... could cut off cancer cell growth at its starting ... University of Texas MD Anderson Cancer Center reported the ... cancer drug target, and MCM7, a protein vital to ... issue of Cancer Cell . , "MCM7 overexpression ...
(Date:6/18/2013)... Two months ago, Suyima Torres, 28, died from respiratory ... of a silicone treatment for gluteus augmentation at Cuerpos Health ... by a mystery Venezuelan doctor in a center that was ... Vazquez of Bayshore Cosmetic Surgery , women suffering from ... not board certified is more common than people think. ...
(Date:6/18/2013)... 18, 2013 David Connett, DO, vice ... Medicine for the College of Osteopathic Medicine of the ... been elected president of the Osteopathic Medical Board ... Jr. appointed Connett, a 1984 alumnus of COMP, to ... elected Connett to the position during a conference call. ...
Breaking Medicine News(10 mins):Health News:Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 3Health News:Scientists catch EGFR passing a crucial message to cancer-promoting protein 2Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 2Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 3
... China should focus on providing affordable medical care for the ... the wealthy minority, the country's health minister said.// ... medical equipment, trying to keep pace with developed countries, and ... Qiang said at a national health conference Saturday, says a ...
... in-hospital cardiac arrests than adults; with appropriate cardiopulmonary resuscitation ... previously thought.// ,These are some findings of ... supervised by Robert A. Berg, MD, professor of pediatrics ... of Medicine. ,The study results have been ...
... Union Minister for Health and Family Welfare, announced that the ... phase of the Reproductive and Child Health Programme called RCH-II.// ... All India Congress of Obstetrics and Gynaecology in Kochi yesterday. ... sector was to reduce the Maternal Mortality Rate, which was ...
... be maintained by a low fat diet into old age, ... counting is unnecessary. The study on nearly 50,000 post-menopausal women ... of the American Medical Association (JAMA), comes to the conclusion ... daily calories was enough to maintain a stable weight. ...
... revealed that more devastating earthquakes are likely to take place ... // They will inflict far greater damage than the 8 ... Bilham who has been working in quake-affected areas of Pakistan ... of energy was stored in the fault line in the ...
... (FOBT) is a simpler way of identifying individuals who ... published online in The Lancet Oncology.// Conventionally, guaiac FOBT ... this cancer, but this new test "could decrease substantially ... for colorectal cancer." ,Lead author Dr Callum G ...
Cached Medicine News:Health News:After Cardiac Arrest, Children Fare Better Than Adults 2Health News:More Severe Earthquakes May Hit Kashmir In Future 2
The AcuMatch M-Series modular femoral stem is a unique, innovative three-piece modular stem designed to address even the most complicated of clinical indications....
The link classic plus hip stem for cemented primary hip replacement surgery...
The uncemented hip joint prosthesis system....
The cemented hip joint prosthesis system....
Medicine Products: